Bli medlem
Bli medlem

Du är här


Ekso GT(TM) Robotic Exoskeleton Cleared by FDA for Use With Stroke and Spinal Cord Injury Patients

Ekso Bionics
Press release

Ekso GT(TM) Robotic Exoskeleton Cleared by FDA for Use With Stroke and Spinal
Cord Injury Patients

First robotic exoskeleton cleared for use with stroke and spinal cord injury
levels to C7

RICHMOND, Calif., 2016-04-04 13:00 CEST (GLOBE NEWSWIRE) -- Ekso Bionics
Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, today announced
that it has received clearance from the U.S. Food and Drug Administration (FDA)
to market its Ekso GT robotic exoskeleton for use in the treatment of
individuals with hemiplegia due to stroke, individuals with spinal cord
injuries at levels T4 to L5, and individuals with spinal cord injuries at
levels of T3 to C7 (ASIA D), in accordance with device’s labeling. The Ekso GT
is the first exoskeleton cleared by the FDA for use with stroke patients.

A video accompanying this release is available at

Photos accompanying this release are available at

Ekso GT is a wearable robotic exoskeleton that enables individuals to stand up
and walk over ground with a full weight bearing, reciprocal gait in a clinical
setting. The Ekso GT with smart Variable Assist* software, which was designed
for rehabilitation institutions, provides adaptive amounts of power to either
side of the patient’s body, engaging the patient throughout his or her
continuum of care. The technology provides the ability to mobilize patients
early in their recovery, frequently, with a significant number of high
intensity steps. To date, the Ekso has helped patients take more than 41
million steps in over 115 rehabilitation institutions around the world.

“This clearance marks a major milestone towards our goal of establishing
exoskeletons as standard of care in the rehabilitation clinic," commented
Thomas Looby, president and interim chief executive officer of Ekso Bionics.
“Our strategy has been to concentrate on the rehabilitation clinic, with a
focus on ease of use, rapid turn over between sessions, and efficacy for a
range of patients. Clinics using the Ekso GT are able to offer exoskeleton
therapy to the widest patient population among all exoskeletons on the market,
which we believe will translate into broader adoption of exoskeletons by
hospitals and rehabilitation clinics and better outcomes for patients.”

Each year, an estimated 375,000 people suffer a spinal cord injury globally and
an estimated 17 million people suffer a stroke.1 Over 60% of acute stroke
survivors are unable to walk or need intervention in walking. Impaired
ambulation is greatly associated with fall risks, dependency, limited
participation in social activities, and poor quality of life. As a consequence,
assisting with ambulation in the clinical environment may aid in the recovery
of ambulation that is one of the most desired goals for stroke survivors
undergoing rehabilitation.2

"We appreciate the collaboration with the leading rehabilitation institutions
who helped contribute to our submission,” added Mr Looby.

"I congratulate Ekso Bionics for being the first exoskeleton to receive
clearance for stroke,” said W. Zev Rymer, Director, Research Planning and
Sensory Motor Performance Program, Rehabilitation Institute of Chicago. "When
we partnered with Ekso at the beginning of 2012, they had the first exoskeleton
that was uniquely optimized for the rehabilitation clinic. We have seen the
clinical value of the technology, and Ekso Bionic's continued innovation now
brings us the ability to provide this advanced technology to a broader patient

1. Feigin VL et al. Lancet
2. Psychometric Comparisons of 3 Functional Ambulation Measures for Patients
With Stroke Jau-Hong Lin et al.

* Marketed as SmartAssist outside of US

About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human
potential by supporting or enhancing strength, endurance and mobility across
medical, industrial and defense applications. Founded in 2005, the company
continues to build upon its unparalleled expertise to design some of the most
cutting-edge, innovative wearable robots available on the market. They are the
only exoskeleton company to offer technologies that range from helping those
with paralysis to stand up and walk, to enhancing human capabilities on job
sites across the globe, to providing research for the advancement of R&D
projects intended to benefit U.S. defense capabilities.

The company is headquartered in the Bay Area and is listed on the OTCQB under
the symbol EKSO. For more information, visit:

About Ekso™ GT
Ekso™ GT is the first FDA cleared exoskeleton cleared for use with stroke, and
spinal cord injury levels to C7. The Ekso GT with smart Variable Assist™
(marketed as SmartAssist outside the U.S.) software is the only exoskeleton
available for rehabilitation institutions that can provide adaptive amounts of
power to either side of the patient’s body, challenging the patient as they
progress through their continuum of care. The suit’s patented technology
provides the ability to mobilize patients earlier, more frequently and with a
greater number of high intensity steps. To date, this device has helped
patients take more than 41 million steps in over 115 rehabilitation
institutions around the world.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking statements may
include, without limitation, statements regarding (i) the plans and objectives
of management for future operations, including plans or objectives relating to
the design, development and commercialization of human exoskeletons, (ii) a
projection of financial results, financial condition, capital expenditures,
capital structure or other financial items, (iii) the Company's future
financial performance and (iv) the assumptions underlying or relating to any
statement described in points (i), (ii) or (iii) above. Such forward-looking
statements are not meant to predict or guarantee actual results, performance,
events or circumstances and may not be realized because they are based upon the
Company's current projections, plans, objectives, beliefs, expectations,
estimates and assumptions and are subject to a number of risks and
uncertainties and other influences, many of which the Company has no control
over. Actual results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking statements as a
result of these risks and uncertainties. Factors that may influence or
contribute to the inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may include,
without limitation, the Company's inability to obtain adequate financing to
fund the Company's operations and necessary to develop or enhance our
technology, the significant length of time and resources associated with the
development of the Company's products, the Company's failure to achieve broad
market acceptance of the Company's products, the failure of our sales and
marketing organization or partners to market our products effectively, adverse
results in future clinical studies of the Company's medical device products,
the failure to obtain or maintain patent protection for the Company's
technology, failure to obtain or maintain regulatory approval to market the
Company's medical devices, lack of product diversification, existing or
increased competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are identified and
described in more detail in the Company's filings with the SEC. To learn more
about Ekso Bionics please visit us at The Company does not
undertake to update these forward-looking statements.

The photos are also available at Newscom,, and via AP

Media Contact:
Heidi Darling, Director of Marketing Communications
Phone: 510-984-1761 x317

Investor Contact:
Debbie Kaster

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.